Biogen Inc. (LON:0R1B)

Biogen Statistics

Total Valuation

Biogen has a market cap or net worth of GBP 13.95 billion. The enterprise value is 16.95 billion.

Market Cap	13.95B
Enterprise Value	16.95B

Important Dates

The next estimated earnings date is Thursday, July 31, 2025.

Earnings Date	Jul 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	146.53M
Shares Outstanding	n/a
Shares Change (YoY)	+0.21%
Shares Change (QoQ)	+0.34%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	146.13M

Valuation Ratios

The trailing PE ratio is 12.18 and the forward PE ratio is 8.05.

PE Ratio	12.18
Forward PE	8.05
PS Ratio	1.84
PB Ratio	1.06
P/TBV Ratio	19.65
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 7.09, with an EV/FCF ratio of 8.99.

EV / Earnings	14.81
EV / Sales	2.31
EV / EBITDA	7.09
EV / EBIT	9.57
EV / FCF	8.99

Financial Position

The company has a current ratio of 1.44, with a Debt / Equity ratio of 0.39.

Current Ratio	1.44
Quick Ratio	0.87
Debt / Equity	0.39
Debt / EBITDA	2.07
Debt / FCF	2.72
Interest Coverage	9.84

Financial Efficiency

Return on equity (ROE) is 9.19% and return on invested capital (ROIC) is 6.48%.

Return on Equity (ROE)	9.19%
Return on Assets (ROA)	5.43%
Return on Invested Capital (ROIC)	6.48%
Return on Capital Employed (ROCE)	10.43%
Revenue Per Employee	999,053
Profits Per Employee	150,554
Employee Count	7,605
Asset Turnover	0.36
Inventory Turnover	1.00

Taxes

In the past 12 months, Biogen has paid 211.38 million in taxes.

Income Tax	211.38M
Effective Tax Rate	15.58%

Stock Price Statistics

The stock price has decreased by -41.84% in the last 52 weeks. The beta is 0.15, so Biogen's price volatility has been lower than the market average.

Beta (5Y)	0.15
52-Week Price Change	-41.84%
50-Day Moving Average	128.14
200-Day Moving Average	146.49
Relative Strength Index (RSI)	48.01
Average Volume (20 Days)	2,191

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.69

Income Statement

In the last 12 months, Biogen had revenue of GBP 7.60 billion and earned 1.14 billion in profits. Earnings per share was 7.83.

Revenue	7.60B
Gross Profit	5.75B
Operating Income	1.84B
Pretax Income	1.36B
Net Income	1.14B
EBITDA	2.38B
EBIT	1.84B
Earnings Per Share (EPS)	7.83

Balance Sheet

The company has 2.01 billion in cash and 5.12 billion in debt, giving a net cash position of -3.11 billion.

Cash & Cash Equivalents	2.01B
Total Debt	5.12B
Net Cash	-3.11B
Net Cash Per Share	n/a
Equity (Book Value)	13.14B
Book Value Per Share	89.70
Working Capital	1.80B

Cash Flow

In the last 12 months, operating cash flow was 2.00 billion and capital expenditures -112.15 million, giving a free cash flow of 1.89 billion.

Operating Cash Flow	2.00B
Capital Expenditures	-112.15M
Free Cash Flow	1.89B
FCF Per Share	n/a

Margins

Gross margin is 75.65%, with operating and profit margins of 24.16% and 15.07%.

Gross Margin	75.65%
Operating Margin	24.16%
Pretax Margin	17.85%
Profit Margin	15.07%
EBITDA Margin	31.39%
EBIT Margin	24.16%
FCF Margin	24.82%

Dividends & Yields

Biogen does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.21%
Shareholder Yield	n/a
Earnings Yield	8.21%
FCF Yield	13.52%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biogen has an Altman Z-Score of 3.17 and a Piotroski F-Score of 6.

Altman Z-Score	3.17
Piotroski F-Score	6